BlackRock Institutional Trust’s Lineage Cell Therapeutics LCTX Stock Holding History

BlackRock Institutional Trust’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$7.41M	Buy	2,344,623 +72,761	+3%	+$223K	﹤0.01%	2575
2016 Q3	$7.75M	Buy	2,271,862 +68,023	+3%	+$188K	﹤0.01%	2490
2016 Q2	$5.03M	Buy	2,203,839 +18,784	+0.9%	+$46.1K	﹤0.01%	2679
2016 Q1	$5.49M	Sell	2,185,055 -190,599	-8%	-$425K	﹤0.01%	2607
2015 Q4	$7.86M	Buy	2,375,654 +103,515	+5%	+$309K	﹤0.01%	2482
2015 Q3	$5.5M	Sell	2,272,139 -87,510	-4%	-$227K	﹤0.01%	2662
2015 Q2	$6.91M	Sell	2,359,649 -8,555	-0.4%	-$33.2K	﹤0.01%	2606
2015 Q1	$9.5M	Buy	2,368,204 +63,274	+3%	+$219K	﹤0.01%	2418
2014 Q4	$6.94M	Buy	2,304,930 +1,011	+0%	+$2.73K	﹤0.01%	2566
2014 Q3	$5.84M	Buy	2,303,919 +120,133	+6%	+$289K	﹤0.01%	2617
2014 Q2	$5.38M	Buy	2,183,786 +126,595	+6%	+$286K	﹤0.01%	2752
2014 Q1	$5.46M	Buy	2,057,191 +267,451	+15%	+$787K	﹤0.01%	2746
2013 Q4	$5.2M	Buy	1,789,740 +152,790	+9%	+$462K	﹤0.01%	2763
2013 Q3	$5.02M	Buy	1,636,950 +37,765	+2%	+$120K	﹤0.01%	2729
2013 Q2	$5.11M	Buy	+1,599,185	New	+$5.12M	﹤0.01%	2687

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BlackRock Institutional Trust's LCTX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Lineage Cell Therapeutics (LCTX) stake by 3.2% in Q4 2016, buying an estimated $223K and bringing the position to 2,344,623 shares worth $7.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2575.

BlackRock Institutional Trust first reported a position in LCTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $9.5M in Q1 2015. 92 funds tracked by Wall St. Rank hold LCTX as of Q4 2016.

BlackRock Institutional Trust held 2,344,623 shares of Lineage Cell Therapeutics worth $7.41M as of Q4 2016.
BlackRock Institutional Trust bought 72,761 Lineage Cell Therapeutics shares in Q4 2016, an estimated $223K.
Lineage Cell Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2575 holding.
BlackRock Institutional Trust first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Lineage Cell Therapeutics position peaked at $9.5M in Q1 2015.
92 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.